Status:
COMPLETED
Study of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease
Lead Sponsor:
Monash University
Conditions:
Vascular Calcification
Arteriosclerosis
Eligibility:
All Genders
18-85 years
Phase:
PHASE4
Brief Summary
Cardiovascular disease (CVD) is the commonest cause of mortality in patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD). Reasons for the greater incidence of CVD in this gro...
Eligibility Criteria
Inclusion
- Subjects with CKD Stage 3 (GFR between 30 and 59ml/min)
- Subjects must be 18 years of age or older
- Willingness to provide written informed consent
Exclusion
- Subjects unable to give informed consent or whom have an expected life-span of less than 3 months
- Subjects undertaking renal replacement therapy (dialysis or transplantation)
- Subjects already taking bisphosphonates
- Subjects with recent fracture (within the last 3 months)
- Subjects scheduled to have a kidney transplant from a known living donor
- Subjects with active gastro-oesophageal reflux disease or peptic ulcer disease
- Subjects who are pregnant or planning on becoming pregnant in the next 18 months
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2009
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00395382
Start Date
January 1 2007
End Date
September 1 2009
Last Update
February 9 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Nephrology, Monash Medical Centre
Clayton, Victoria, Australia, 3168